Other languages DURECT Corporation Deutsche Boerse AG

Equities

DC8A

US2666055007

Real-time Estimate Tradegate Other stock markets 02:34:11 2024-07-17 pm EDT			5-day change	1st Jan Change
1.305 ^EUR	+8.75%		+1.68%	+130.48%

May. 21	DURECT Corporation Receives FDA Breakthrough Therapy Designation for Larsucosterol in Alcohol-Associated Hepatitis	CI
May. 21	Sector Update: Health Care Stocks Edge Higher Tuesday Afternoon	MT

Other languages

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

DURECT Corporation Receives FDA Breakthrough Therapy Designation for Larsucosterol in Alcohol-Associated Hepatitis	May. 21
Sector Update: Health Care Stocks Edge Higher Tuesday Afternoon	May. 21
Durect Gets FDA Breakthrough Therapy Designation for Alcohol-Related Hepatitis Treatment	May. 21
Durect Far From Earnings Story But FDA Commentary Shows Path Forward, Oppenheimer Says	May. 14
DURECT Corporation Reports Earnings Results for the First Quarter Ended March 31, 2024	May. 13
DURECT Corporation Reports Earnings Results for the Full Year Ended December 31, 2023	Mar. 27
DURECT Corporation Reports Earnings Results for the Fourth Quarter Ended December 31, 2023	Mar. 27
DURECT Corporation and Charles River Laboratories Enter into Co-Marketing and Collaboration Agreement for Alzet® Product Line in U.S. and Canada	Mar. 04
DURECT Corporation Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	Nov. 13
Sector Update: Health Care Stocks Mixed Late Wednesday Afternoon	Nov. 08
Sector Update: Health Care	Nov. 08
Top Midday Decliners	Nov. 08
Top Premarket Decliners	Nov. 08
DURECT Corporation Announces Topline Results from Phase 2b AHFIRM Trial of Larsucosterol in Alcohol-Associated Hepatitis with Promising Effect on Mortality	Nov. 07
Durect Corporation Announces Last Patient Last Visit in Phase 2B Ahfirm Trial of Larsucosterol in Alcohol-Associated Hepatitis	23-09-07
DURECT Corporation Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023	23-08-09
Durect to Offer 3 Million Shares, Accompanying Warrants for Gross Proceeds of $15 Million; Stock Slumps	23-07-20
DURECT Corporation Completes Enrollment in Phase 2b AHFIRM Trial of Larsucosterol in Alcohol-Associated Hepatitis	23-06-07
Durect Completes Patient Enrollment in Severe Alcohol-Associated Hepatitis Treatment Phase 2 Trial	23-06-07
DURECT Corporation Reports Earnings Results for the First Quarter Ended March 31, 2023	23-05-08

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Other languages DURECT Corporation Deutsche Boerse AG

Equities

DC8A

US2666055007

Other languages

Filters